-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

EF Hutton Maintains Buy on ATAI Life Sciences, Lowers Price Target to $15

Benzinga · 01/06/2023 12:07
EF Hutton analyst Elemer Piros maintains ATAI Life Sciences (NASDAQ:ATAI) with a Buy and lowers the price target from $23 to $15.